HokieHead
3 years ago
In here for some off of Bidenβs speech.
Even before the pandemic, Fulgent's market capitalization tripled in 2019 with 52% sales growth. Last year, COVID-19 pushed growth off the charts. Revenue rose 1,200% on the back of a 74-fold increase in testing volume. Beyond the numbers, the company established important relationships with state health departments, school systems, employers, and insurers.
The company ended the third quarter with $104 million cash and zero debt on its balance sheet.
Fulgent Genetics has also revised its fiscal 2020 revenue guidance from $135 million to $235 million on Nov. 9 and then to $300 million on Nov. 23, thanks to the ever-increasing demand for its COVID-19 tests.